UPDATE 1-Bristol matches estimates, but new blood clot drug struggles
July 25 (Reuters) - Bristol-Myers Squibb Co reported quarterly results that matched expectations, but the company posted paltry sales of its new Eliquis drug that prevents blood clots, and cut its 2013 profit forecast.
The company on Thursday said it earned $536 million, or 32 cents per share, in the quarter. That compared with $645 million, or 38 cents per share, in the year-earlier quarter.
Excluding special items, including combined charges of $274 million for restructuring and pension settlements, Bristol-Myers earned 44 cents per share, matching the forecast of Thomson Reuters I/B/E/S.
Global revenue fell 9 percent to $4.05 billion, in line with Wall Street expectations, hurt by generic competition for the company's Plavix blood clot preventer and its Avapro blood pressure treatment.
The company trimmed its full-year 2013 profit forecast to between $1.70 and $1.78 per share, from its earlier view of $1.78 to $1.88.